

PATsmart™ ZipChip® System: Architecture of Autoinhibited and Active BRAF–MEK1–14–3–3 Complexes

Eunyoung Park, Shaun Rawson, Kunhua Li,
Byeong-Won Kim, Scott B. Ficarro, Gonzalo
Gonzalez-Del Pino, Humayun Sharif, Jarrod A.
Marto, Hyesung Jeon and Michael J. Eck

*Repligen Corp. now owns the life sciences PAT
product portfolio of 908 Devices Inc. Please
contact Repligen for further inquiries.*

Nature, Architecture of autoinhibited and active
BRAF–MEK1–14–3–3 complexes.

DOI: 10.1038/s41586-019-1660-y Publication
Date (Web): October 3, 2019

Copyright © 2019

Contact

Repligen Corporation
685 Route 202/206
Bridgewater, NJ, USA 08807
analytics-support@repligen.com
(908) 707-1009

Technical Note

Abstract

RAF family kinases are RAS-activated switches that initiate signaling through the MAP kinase cascade to control cellular proliferation, differentiation, and survival^{1,2,3}. RAF activity is tightly regulated and inappropriate activation is a frequent cause of cancer^{4,5,6}; however, the structural basis for RAF regulation is poorly understood at present. Here we use cryo-electron microscopy to determine autoinhibited and active-state structures of full-length BRAF in complexes with MEK1 and a 14-3-3 dimer. The reconstruction reveals an inactive BRAF–MEK1 complex restrained in a cradle formed by the 14-3-3 dimer, which binds the phosphorylated S365 and S729 sites that flank the BRAF kinase domain. The BRAF cysteine-rich domain occupies a central position that stabilizes this assembly, but the adjacent RAS-binding domain is poorly ordered and peripheral. The 14-3-3 cradle maintains autoinhibition by sequestering the membrane-binding cysteine-rich domain and blocking dimerization of the BRAF kinase domain. In the active state, these inhibitory interactions are released, and a single 14-3-3 dimer rearranges to bridge the C-terminal pS729 binding sites of two BRAFs, which drives the formation of an active, back-to-back BRAF dimer. Our structural snapshots provide a foundation for understanding normal RAF regulation and its mutational disruption in cancer and developmental syndromes.

[Click here](#) to view the entire article.